Lipe & Dalton’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $46K | Hold |
800
| – | – | 0.02% | 87 |
|
|
2026
Q1 | $49K | Hold |
800
| – | – | 0.03% | 85 |
|
|
2025
Q4 | $43K | Sell |
800
-1,150
| -59% | -$55.3K | 0.02% | 88 |
|
|
2025
Q3 | $88K | Sell |
1,950
-70
| -3% | -$3.27K | 0.04% | 83 |
|
|
2025
Q2 | $94K | Sell |
2,020
-54,979
| -96% | -$2.7M | 0.05% | 80 |
|
|
2025
Q1 | $3.48M | Buy |
56,999
+230
| +0.4% | +$13.4K | 1.95% | 19 |
|
|
2024
Q4 | $3.21M | Buy |
56,769
+208
| +0.4% | +$11.6K | 1.7% | 20 |
|
|
2024
Q3 | $2.93M | Sell |
56,561
-590
| -1% | -$27.7K | 1.48% | 25 |
|
|
2024
Q2 | $2.37M | Sell |
57,151
-1,530
| -3% | -$68.5K | 1.28% | 28 |
|
|
2024
Q1 | $3.18M | Buy |
58,681
+450
| +0.8% | +$22.9K | 1.64% | 22 |
|
|
2023
Q4 | $2.99M | Sell |
58,231
-470
| -0.8% | -$24.7K | 1.62% | 20 |
|
|
2023
Q3 | $3.41M | Sell |
58,701
-190
| -0.3% | -$11.6K | 2.05% | 19 |
|
|
2023
Q2 | $3.77M | Sell |
58,891
-580
| -1% | -$38.9K | 2.15% | 15 |
|
|
2023
Q1 | $4.12M | Sell |
59,471
-17,289
| -23% | -$1.22M | 2.36% | 15 |
|
|
2022
Q4 | $5.52M | Sell |
76,760
-103
| -0.1% | -$7.77K | 3.18% | 9 |
|
|
2022
Q3 | $5.46M | Buy |
76,863
+101
| +0.1% | +$7.33K | 3.43% | 7 |
|
|
2022
Q2 | $5.91M | Sell |
76,762
-149
| -0.2% | -$11.3K | 3.46% | 6 |
|
|
2022
Q1 | $5.62M | Sell |
76,911
-523
| -0.7% | -$35.1K | 2.74% | 13 |
|
|
2021
Q4 | $4.83M | Buy |
77,434
+1,216
| +2% | +$71.3K | 2.28% | 13 |
|
|
2021
Q3 | $4.51M | Buy |
76,218
+4,416
| +6% | +$291K | 2.32% | 15 |
|
|
2021
Q2 | $4.8M | Buy |
71,802
+512
| +0.7% | +$33.4K | 2.49% | 13 |
|
|
2021
Q1 | $4.5M | Buy |
71,290
+76
| +0.1% | +$4.73K | 2.5% | 14 |
|
|
2020
Q4 | $4.42M | Sell |
71,214
-324
| -0.5% | -$19.9K | 2.72% | 9 |
|
|
2020
Q3 | $4.31M | Sell |
71,538
-223
| -0.3% | -$13.4K | 3% | 7 |
|
|
2020
Q2 | $4.22M | Sell |
71,761
-1,279
| -2% | -$76.5K | 3.06% | 6 |
|
|
2020
Q1 | $4.07M | Sell |
73,040
-1,404
| -2% | -$85.8K | 3.44% | 5 |
|
|
2019
Q4 | $4.78M | Buy |
74,444
+3,676
| +5% | +$211K | 3.17% | 8 |
|
|
2019
Q3 | $3.59M | Sell |
70,768
-2,328
| -3% | -$109K | 2.62% | 13 |
|
|
2019
Q2 | $3.31M | Sell |
73,096
-353
| -0.5% | -$16.4K | 2.37% | 15 |
|
|
2019
Q1 | $3.5M | Sell |
73,449
-629
| -0.8% | -$31.3K | 2.58% | 15 |
|
|
2018
Q4 | $3.85M | Buy |
74,078
+7,551
| +11% | +$406K | 3.14% | 11 |
|
|
2018
Q3 | $4.13M | Sell |
66,527
-49
| -0.1% | -$2.91K | 2.82% | 14 |
|
|
2018
Q2 | $3.68M | Sell |
66,576
-1,150
| -2% | -$62.1K | 2.71% | 16 |
|
|
2018
Q1 | $4.28M | Buy |
67,726
+582
| +0.9% | +$37.4K | 3.06% | 10 |
|
|
2017
Q4 | $4.12M | Sell |
67,144
-1,005
| -1% | -$62.9K | 2.84% | 15 |
|
|
2017
Q3 | $4.34M | Buy |
68,149
+940
| +1% | +$54.9K | 3.05% | 11 |
|
|
2017
Q2 | $3.75M | Buy |
67,209
+5,030
| +8% | +$274K | 2.43% | 16 |
|
|
2017
Q1 | $3.38M | Buy |
62,179
+2,730
| +5% | +$150K | 2.45% | 19 |
|
|
2016
Q4 | $3.47M | Buy |
+59,449
| New | +$3.25M | 2.47% | 18 |
|
|
2016
Q3 | – | Sell |
-2,305
| Closed | -$170K | – | 82 |
|
|
2016
Q2 | $170K | Sell |
2,305
-150
| -6% | -$10.6K | 0.12% | 91 |
|
|
2016
Q1 | $157K | Hold |
2,455
| – | – | 0.12% | 67 |
|
|
2015
Q4 | $169K | Buy |
+2,455
| New | +$162K | 0.14% | 64 |
|
Other funds holding BMY
Lipe & Dalton's BMY Position: Q2 2026 in Review
Lipe & Dalton held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 800 shares worth $46K. The position accounts for 0.02% of the portfolio, ranked #87.
Lipe & Dalton first reported a position in BMY in Q4 2015 and has held it in 42 quarters since. The position peaked at $5.91M in Q2 2022. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Lipe & Dalton held 800 shares of Bristol-Myers Squibb worth $46K as of Q2 2026.
- Lipe & Dalton left its Bristol-Myers Squibb share count unchanged in Q2 2026.
- Bristol-Myers Squibb made up 0.02% of Lipe & Dalton's portfolio in Q2 2026, its #87 holding.
- Lipe & Dalton first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 42 quarters since.
- Lipe & Dalton's Bristol-Myers Squibb position peaked at $5.91M in Q2 2022.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.